Impedimed Ltd (ASX: IPD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Impedimed Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$117.34 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.02 billion
Earnings per share
-0.010
Dividend per share
N/A
Year To Date Return
-68.28%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Impedimed Ltd (ASX: IPD)
Latest News
Share Market News
2 ASX All Ords shares tumbling following leadership shakeups
Healthcare Shares
3 ASX healthcare stocks that have more than doubled in a year
Share Fallers
Why Brainchip, Impedimed, Northern Star, and Telix shares are falling today
Share Fallers
Why Dusk, Impedimed, Nufarm, and Weebit Nano shares are falling
Healthcare Shares
Guess which ASX biotech share just rocketed 86% on 'a major validating moment'
Earnings Results
3 ASX All Ords shares making moves today following earnings, one up 16%
Earnings Results
3 ASX All Ords shares tumbling lower following full-year results
Healthcare Shares
Impedimed (ASX:IPD) share price dips following capital raising update
Healthcare Shares
What's going on with the Impedimed (ASX:IPD) share price?
Share Gainers
The Impedimed (ASX:IPD) share price is up 10% on trial success
Share Market News
Why the Impedimed (ASX:IPD) share price is rocketing 9% today
Share Gainers
Impedimed (ASX:IPD) share price rises with 46% lift in revenues
Frequently Asked Questions
-
No, Impedimed does not pay shareholder dividends at this time.
-
Impedimed Limited listed on the ASX on 24 October 2007.
IPD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Impedimed Ltd
Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.
The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.
As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America.
IPD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 04 Oct 2024 | $0.06 | $0.00 | 0.00% | 820,743 | $0.06 | $0.06 | $0.06 |
| 03 Oct 2024 | $0.06 | $0.00 | 0.00% | 833,425 | $0.06 | $0.06 | $0.06 |
| 02 Oct 2024 | $0.06 | $0.00 | 0.00% | 1,375,806 | $0.06 | $0.06 | $0.06 |
| 01 Oct 2024 | $0.06 | $0.00 | 0.00% | 843,396 | $0.06 | $0.06 | $0.06 |
| 30 Sep 2024 | $0.06 | $0.00 | 0.00% | 448,756 | $0.06 | $0.06 | $0.06 |
| 27 Sep 2024 | $0.06 | $0.00 | 0.00% | 428,743 | $0.06 | $0.06 | $0.06 |
| 26 Sep 2024 | $0.06 | $0.00 | 0.00% | 2,686,033 | $0.06 | $0.06 | $0.05 |
| 25 Sep 2024 | $0.06 | $0.00 | 0.00% | 1,044,202 | $0.06 | $0.06 | $0.05 |
| 24 Sep 2024 | $0.06 | $0.00 | 0.00% | 5,027,981 | $0.06 | $0.07 | $0.05 |
| 23 Sep 2024 | $0.06 | $0.01 | 18.87% | 3,672,687 | $0.06 | $0.06 | $0.06 |
| 20 Sep 2024 | $0.05 | $0.00 | 0.00% | 3,783,470 | $0.05 | $0.06 | $0.05 |
| 19 Sep 2024 | $0.05 | $0.00 | 0.00% | 996,185 | $0.05 | $0.05 | $0.05 |
| 18 Sep 2024 | $0.05 | $0.00 | 0.00% | 1,685,278 | $0.05 | $0.05 | $0.05 |
| 17 Sep 2024 | $0.05 | $0.00 | 0.00% | 455,114 | $0.05 | $0.05 | $0.05 |
| 16 Sep 2024 | $0.05 | $0.00 | 0.00% | 450,385 | $0.05 | $0.05 | $0.05 |
| 13 Sep 2024 | $0.05 | $0.00 | 0.00% | 1,855,943 | $0.05 | $0.05 | $0.05 |
| 12 Sep 2024 | $0.05 | $0.01 | 22.73% | 4,892,824 | $0.04 | $0.05 | $0.04 |
| 11 Sep 2024 | $0.04 | $0.00 | 0.00% | 7,306,742 | $0.04 | $0.04 | $0.04 |
| 10 Sep 2024 | $0.04 | $0.00 | 0.00% | 6,265,281 | $0.05 | $0.05 | $0.04 |
| 09 Sep 2024 | $0.05 | $0.00 | 0.00% | 258,968 | $0.05 | $0.05 | $0.05 |
| 06 Sep 2024 | $0.05 | $0.00 | 0.00% | 1,564,009 | $0.05 | $0.05 | $0.05 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Sep 2024 | Andrew Grant | Buy | 600,000 | $28,530 |
On-market trade.
|
| 30 Aug 2024 | Andrew Grant | Buy | 1,000,000 | $49,600 |
On-market trade.
|
| 30 Aug 2024 | Christine Emmanuel-Donnelly | Buy | 200,000 | $10,000 |
On-market trade.
|
| 14 May 2024 | Christine Emmanuel-Donnelly | Buy | 100,000 | $8,000 |
On-market trade.
|
| 08 May 2024 | Janelle Delaney | Buy | 634,177 | $50,099 |
On-market trade.
|
| 06 May 2024 | Andrew Grant | Buy | 100,000 | $8,050 |
On-market trade.
|
| 25 Mar 2024 | Janelle Delaney | Buy | 568,181 | $49,999 |
On-market trade.
|
| 22 Mar 2024 | Janelle Delaney | Buy | 581,395 | $49,999 |
On-market trade.
|
| 04 Mar 2024 | Janelle Delaney | Buy | 1,137,634 | $99,591 |
On-market trade.
|
| 29 Feb 2024 | Andrew Grant | Buy | 100,000 | $87,000 |
On-market trade.
|
| 28 Feb 2024 | Andrew Grant | Buy | 130,000 | $10,920 |
On-market trade.
|
| 28 Feb 2024 | Christine Emmanuel-Donnelly | Buy | 121,952 | $10,169 |
On-market trade.
|
| 14 Dec 2023 | Janelle Delaney | Buy | 942,232 | $135,148 |
On-market trade.
|
| 13 Dec 2023 | Christine Emmanuel-Donnelly | Buy | 67,857 | $9,499 |
On-market trade.
|
| 05 Dec 2023 | Janelle Delaney | Buy | 66,503 | $8,977 |
On-market trade.
|
| 04 Dec 2023 | Andrew Grant | Buy | 70,000 | $9,625 |
On-market trade.
|
| 20 Nov 2023 | Richard Valencia | Expiry | 20,000,000 | $2,600,000 |
As advised by the company. Lapse of Options and Performance Rights
|
| 20 Nov 2023 | Richard Valencia | Expiry | 10,000,000 | $1,300,000 |
Options expired.
|
| 01 Nov 2023 | Christine Emmanuel-Donnelly | Buy | 100,000 | $10,500 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Parmjot Bains | Managing DirectorChief Executive Officer | Jan 2024 |
Dr Bains is a medical doctor with more than 30 years of diverse healthcare experience including Pfizer and McKinsey across the United States, Asia, Middle East and Australia.
|
| Mr Andrew John Grant | Non-Executive Director | Sep 2023 |
Mr Grant has spent more than 20 years in gaining understanding and experience working with key US customers and across global healthcare markets. He has Strategic planning experience and delivery in healthcare working with leading healthcare organisations globally, including McKinsey and ResMed. He is also a member of Risk Committee.
|
| Mr McGregor Grant | Executive ChairmanExecutive DirectorChief Financial Officer | Feb 2024 |
Mr Grant brings Broad commercial and financial experience in growing successful global medical device businesses, most recently Nanosonics Limited. He has Board administration, governance and investor relations experience.
|
| Ms Christine Emmanuel-Donnelly | Non-Executive Director | Sep 2023 |
Ms Emmanuel-Donnelly brings 30 years in IP expertise through commercialisation and strategic in-house intellectual property roles. She has more than 4 years in Board and healthcare governance experience. She is a member of the Risk Committee.
|
| Ms Janelle Delaney | Non-Executive Director | Sep 2023 |
Ms Delaney has 30 years of project management and execution at IBM, with responsibility for the quality of delivery across Asia Pacific's portfolio of several thousand projects. She is a member of Risk Committee.
|
| Ms Fiona Bones | Non-Executive Director | Jun 2024 |
Ms Bones brings more than 30 years of experience in the finance, corporate governance and systems transformation. She has global governance experience gained as Vice President of Finance, International Controller of Google for 20 years. She is Chair of the Risk Committee.
|
| Ms Leanne Ralph | Company Secretary | Jan 2015 |
-
|
| Steven Chen | Chief Medical Officer |
-
|
|
| Leanne Ralph | Company Secretary |
-
|
|
| Ashley Munoz | Director Human Resources |
-
|
|
| Andrew Grant | Executive Director VP Product Development & Customer Solutions |
-
|
|
| Julie Kuhlken | Senior Director Downstream Marketing |
-
|
|
| Dennis Schlaht | SVP R&D and Technology |
-
|
|
| Tim Benkovic | SVP Sales & Customer Success |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 177,180,440 | 8.76% |
| HSBC Custody Nominees (Australia) Limited | 164,419,200 | 8.13% |
| Jp Morgan Nominees Australia Pty Limited | 148,941,253 | 7.36% |
| National Nominees Limited | 115,304,879 | 5.70% |
| HSBC Custody Nominees (Australia) Limited i | 55,570,348 | 2.75% |
| BNP Paribas Noms Pty Ltd | 34,426,377 | 1.70% |
| Sunlora Pty Ltd | 32,125,000 | 1.59% |
| Moore Family Nominee Pty Ltd | 30,000,000 | 1.48% |
| Mr Hamish Alexander Jones | 23,538,705 | 1.16% |
| Mba Investments Pty Ltd | 22,490,990 | 1.11% |
| Mr Gregory Wayne Brown | 20,300,000 | 1.00% |
| Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken | 19,000,000 | 0.94% |
| Bnp Paribas Nominees Pty Ltd i | 18,925,694 | 0.94% |
| Pakasoluto Pty Limited | 16,011,422 | 0.79% |
| Mr Hsien Michael Soo | 15,662,797 | 0.77% |
| First Samuel Ltd Acn 086243567 | 15,281,508 | 0.76% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 14,251,964 | 0.70% |
| Bsd Pty Ltd | 13,495,000 | 0.67% |
| Hme Soo Holdings Pty Ltd | 12,320,921 | 0.61% |
| Bnp Paribas Nominees Pty Ltd ii | 11,693,112 | 0.58% |
